IA Trial Radar | ||
|---|---|---|
O estudo clínico NCT03159546 para Diabetes mellitus está concluído. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui. | ||
AbbottFreeStyle Libre Flash Glucose Monitoring System Accuracy 50 Randomizado Multicêntrico
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
- ADC-US-VAL-17165
| Grupo de participantes/Braço | Intervenção/Tratamento |
|---|---|
N/A | Device: FreeStyle Libre Flash Glucose Monitoring System Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes. |
| Medida de desfecho | Descrição da medida | Prazo |
|---|---|---|
System Performance | System performance will be characterized with respect to YSI reference venous plasma sample measurements. | Approximately 32 hours |
System Related adverse device effects | System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants. | Up to 42 days |
- Subject must be at least 18 years of age.
- Subject must have type 1 or type 2 diabetes.
- Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
- Willing to perform a minimum of 8 finger sticks per day during the study.
- Subject must be willing to fast four individual times prior to in-clinic visits, each fast lasting a minimum of eight hours.
- Subject must be able to read and understand English.
- In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
- Subject must be available to participate in all study visits.
- Subject must be willing and able to provide written signed and dated informed consent.
Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
Subject is pregnant, attempting to conceive or not willing and able to practice birth control during the study duration (applicable to female subjects only).
Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
Subject currently is participating in another clinical trial.
Subject has donated blood within 112 days (3.7 months) prior to the beginning of the study activities.
Subject is anemic.
Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff. Such conditions include but are not limited to:
o History of HIV, Hepatitis B or C
Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
Subject is unsuitable for participation due to any other cause as determined by the Investigator.
AbbottCalifornia
Idaho
Washington